NAVIGEN, INC.
Biotech · Private
D-peptide TNF-α inhibitors for oral delivery to treat inflammatory bowel disease
nvgn.com →- Grants
- $18M
- 22 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 1 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic D-peptide Inhibitor of HIV Entry | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Treating Acute Lung Injury via Cytokine Signaling Blockade | $224,632 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Protease resistant D peptide Inhibitors of Ebola Virus Entry | $2,894,941 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Protease-resistant D-peptide Inhibitors of Ebola Virus Entry | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Arf6 inhibitors for the treatment of uveal melanoma | $298,731 | |
| Federal grant | Department of Health and Human Services · Phase I · Highly specific anti-toxin therapies for severe bacterial gut infections | $299,943 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a Peripherally-Acting Peptidic Galanin Analog for Treatment of Postoperative Pain | $290,919 | |
| Federal grant | Department of Health and Human Services · Phase II · Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr | $755,418 | |
| Federal grant | Department of Health and Human Services · Phase II · Protease-resistant D-peptide Inhibitors of Ebola Virus Entry | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Highly specific anti-toxin therapies for severe bacterial gut infections | $297,401 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a potent D-peptide RSV inhibitor | $2,992,259 | |
| Federal grant | Department of Health and Human Services · Phase II · Protease-resistant D-peptide Inhibitors of Ebola Virus Entry | $894,941 | |
| Federal grant | Department of Health and Human Services · Phase II · ARF6 Inhibitors for Treatment of Acute Lung Injury | $1,706,740 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a potent D-peptide RSV inhibitor | $999,998 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · D-peptide inhibitors of SIRPα anti-phagocytic signaling | $299,945 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · D peptide inhibitors of SIRPα anti phagocytic signaling | $299,945 | |
| Federal grant | Department of Health and Human Services · Phase II · ARF6 Inhibitors for Treatment of Acute Lung Injury | $817,279 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of a potent D-peptide RSV inhibitor | $999,998 | |
| Federal grant | Department of Health and Human Services · Phase I · ARF6 Inhibitor as Adjunctive Therapy for Treatment of SA Bacteremia | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease | $216,252 | |
| Federal grant | Department of Health and Human Services · Phase I · Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease | $106,814 | |
| Federal grant | Department of Health and Human Services · Phase I · Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza | $268,075 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3289 | Exuma Biotech Corp. | — | $133M |
| 3290 | Fortify Therapeutics | — | — |
| 3291 | Jade Biosciences | — | — |
| 3292 | NAVIGEN, INC. | — | — |
| 3293 | Oryn Therapeutics, Inc. | — | — |
| 3294 | Inflamma Therapeutics, LLC | — | — |
| 3295 | CELLCHORUS INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- ARF6 Inhibitors And Related Methodsgranted
- Tnf-alpha Binding Agents And Methods Of Using The Sameapplication
- TNFalpha BINDING AGENTS AND METHODS USING THE SAMEapplication
- ARF6 Inhibitors And Methods Of Synthesis And Use Thereofapplication
- Tnf-alpha Binding Agents And Methods Of Using The Sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.